XML 49 R28.htm IDEA: XBRL DOCUMENT
v3.23.1

Segments of Business and Geographic Areas (Tables) | 3 Months Ended
--- | ---
Apr. 02, 2023
Segment Reporting [Abstract] |
Sales By Segment Of Business | SALES BY SEGMENT OF BUSINESS
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | Percent Change |  |  |  |  |  |
CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  |
OTC |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | $ | 745 |  |  | 670 |  |  | 11.0 | % |  |  |  |  |  |
International |  | 897 |  |  | 791 |  |  | 13.5 |  |  |  |  |  |  |
Worldwide |  | 1,642 |  |  | 1,461 |  |  | 12.4 |  |  |  |  |  |  |
Skin Health/Beauty |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 617 |  |  | 544 |  |  | 13.4 |  |  |  |  |  |  |
International |  | 493 |  |  | 468 |  |  | 5.3 |  |  |  |  |  |  |
Worldwide |  | 1,110 |  |  | 1,012 |  |  | 9.7 |  |  |  |  |  |  |
Oral Care |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 159 |  |  | 143 |  |  | 11.6 |  |  |  |  |  |  |
International |  | 202 |  |  | 223 |  |  | (9.6) |  |  |  |  |  |  |
Worldwide |  | 361 |  |  | 366 |  |  | (1.3) |  |  |  |  |  |  |
Baby Care |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 96 |  |  | 85 |  |  | 13.0 |  |  |  |  |  |  |
International |  | 263 |  |  | 270 |  |  | (2.8) |  |  |  |  |  |  |
Worldwide |  | 359 |  |  | 355 |  |  | 1.0 |  |  |  |  |  |  |
Women’s Health |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3 |  |  | 3 |  |  | 1.8 |  |  |  |  |  |  |
International |  | 214 |  |  | 224 |  |  | (4.9) |  |  |  |  |  |  |
Worldwide |  | 217 |  |  | 228 |  |  | (4.8) |  |  |  |  |  |  |
Wound Care/Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 115 |  |  | 112 |  |  | 2.6 |  |  |  |  |  |  |
International |  | 49 |  |  | 52 |  |  | (6.0) |  |  |  |  |  |  |
Worldwide |  | 164 |  |  | 164 |  |  | (0.1) |  |  |  |  |  |  |
TOTAL CONSUMER HEALTH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,735 |  |  | 1,557 |  |  | 11.4 |  |  |  |  |  |  |
International |  | 2,117 |  |  | 2,029 |  |  | 4.4 |  |  |  |  |  |  |
Worldwide |  | 3,852 |  |  | 3,586 |  |  | 7.4 |  |  |  |  |  |  |
PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  |
Immunology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 2,448 |  |  | 2,501 |  |  | (2.1) |  |  |  |  |  |  |
International |  | 1,664 |  |  | 1,617 |  |  | 2.9 |  |  |  |  |  |  |
Worldwide |  | 4,112 |  |  | 4,119 |  |  | (0.2) |  |  |  |  |  |  |
REMICADE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 276 |  |  | 358 |  |  | (22.8) |  |  |  |  |  |  |
U.S. Exports |  | 41 |  |  | 80 |  |  | (48.8) |  |  |  |  |  |  |
International |  | 170 |  |  | 225 |  |  | (24.4) |  |  |  |  |  |  |
Worldwide |  | 487 |  |  | 663 |  |  | (26.5) |  |  |  |  |  |  |
SIMPONI / SIMPONI ARIA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 271 |  |  | 287 |  |  | (5.6) |  |  |  |  |  |  |
International |  | 266 |  |  | 283 |  |  | (6.1) |  |  |  |  |  |  |
Worldwide |  | 537 |  |  | 571 |  |  | (5.8) |  |  |  |  |  |  |
STELARA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,451 |  |  | 1,379 |  |  | 5.2 |  |  |  |  |  |  |
International |  | 993 |  |  | 909 |  |  | 9.3 |  |  |  |  |  |  |
Worldwide |  | 2,444 |  |  | 2,288 |  |  | 6.8 |  |  |  |  |  |  |
TREMFYA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 406 |  |  | 391 |  |  | 3.9 |  |  |  |  |  |  |
International |  | 234 |  |  | 199 |  |  | 17.3 |  |  |  |  |  |  |
Worldwide |  | 640 |  |  | 590 |  |  | 8.4 |  |  |  |  |  |  |
OTHER IMMUNOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3 |  |  | 6 |  |  | (51.2) |  |  |  |  |  |  |
International |  | 0 |  | 0 |  | — |  |  |  |  |  |  |
Worldwide |  | 3 |  |  | 6 |  |  | (51.3) |  |  |  |  |  |  |
Infectious Diseases |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 392 |  |  | 461 |  |  | (14.9) |  |  |  |  |  |  |
International |  | 1,193 |  |  | 836 |  |  | 42.8 |  |  |  |  |  |  |
Worldwide |  | 1,586 |  |  | 1,297 |  |  | 22.3 |  |  |  |  |  |  |
COVID-19 VACCINE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 0 |  | 75 |  |  | * |  |  |  |  |  |
International |  | 747 |  |  | 382 |  |  | 95.6 |  |  |  |  |  |  |
Worldwide |  | 747 |  |  | 457 |  |  | 63.4 |  |  |  |  |  |  |
EDURANT / rilpivirine |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 9 |  |  | 9 |  |  | (1.4) |  |  |  |  |  |  |
International |  | 271 |  |  | 239 |  |  | 13.4 |  |  |  |  |  |  |
Worldwide |  | 280 |  |  | 248 |  |  | 12.8 |  |  |  |  |  |  |
PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 378 |  |  | 369 |  |  | 2.5 |  |  |  |  |  |  |
International |  | 99 |  |  | 132 |  |  | (25.2) |  |  |  |  |  |  |
Worldwide |  | 477 |  |  | 501 |  |  | (4.8) |  |  |  |  |  |  |
OTHER INFECTIOUS DISEASES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 5 |  |  | 8 |  |  | (33.1) |  |  |  |  |  |  |
International |  | 77 |  |  | 83 |  |  | (7.6) |  |  |  |  |  |  |
Worldwide |  | 82 |  |  | 91 |  |  | (9.8) |  |  |  |  |  |  |
Neuroscience |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 978 |  |  | 843 |  |  | 16.0 |  |  |  |  |  |  |
International |  | 826 |  |  | 898 |  |  | (8.1) |  |  |  |  |  |  |
Worldwide |  | 1,804 |  |  | 1,741 |  |  | 3.6 |  |  |  |  |  |  |
CONCERTA / methylphenidate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 70 |  |  | 35 |  |  | * |  |  |  |  |  |
International |  | 136 |  |  | 122 |  |  | 11.4 |  |  |  |  |  |  |
Worldwide |  | 206 |  |  | 157 |  |  | 31.4 |  |  |  |  |  |  |
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 713 |  |  | 661 |  |  | 7.9 |  |  |  |  |  |  |
International |  | 331 |  |  | 387 |  |  | (14.6) |  |  |  |  |  |  |
Worldwide |  | 1,044 |  |  | 1,048 |  |  | (0.4) |  |  |  |  |  |  |
SPRAVATO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 111 |  |  | 61 |  |  | 82.4 |  |  |  |  |  |  |
International |  | 20 |  |  | 9 |  |  | * |  |  |  |  |  |
Worldwide |  | 131 |  |  | 70 |  |  | 86.9 |  |  |  |  |  |  |
OTHER NEUROSCIENCE(1) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 84 |  |  | 86 |  |  | (3.5) |  |  |  |  |  |  |
International |  | 339 |  |  | 380 |  |  | (10.7) |  |  |  |  |  |  |
Worldwide |  | 423 |  |  | 467 |  |  | (9.4) |  |  |  |  |  |  |
Oncology |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,889 |  |  | 1,582 |  |  | 19.4 |  |  |  |  |  |  |
International |  | 2,223 |  |  | 2,369 |  |  | (6.1) |  |  |  |  |  |  |
Worldwide |  | 4,112 |  |  | 3,950 |  |  | 4.1 |  |  |  |  |  |  |
CARVYKTI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 70 |  |  | — |  |  | * |  |  |  |  |  |
International |  | 2 |  |  | — |  |  | * |  |  |  |  |  |
Worldwide |  | 72 |  |  | — |  |  | * |  |  |  |  |  |
DARZALEX |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,191 |  |  | 953 |  |  | 25.0 |  |  |  |  |  |  |
International |  | 1,072 |  |  | 903 |  |  | 18.8 |  |  |  |  |  |  |
Worldwide |  | 2,264 |  |  | 1,856 |  |  | 22.0 |  |  |  |  |  |  |
ERLEADA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 249 |  |  | 206 |  |  | 21.2 |  |  |  |  |  |  |
International |  | 293 |  |  | 194 |  |  | 50.9 |  |  |  |  |  |  |
Worldwide |  | 542 |  |  | 400 |  |  | 35.6 |  |  |  |  |  |  |
IMBRUVICA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 270 |  |  | 370 |  |  | (27.1) |  |  |  |  |  |  |
International |  | 557 |  |  | 668 |  |  | (16.6) |  |  |  |  |  |  |
Worldwide |  | 827 |  |  | 1,038 |  |  | (20.3) |  |  |  |  |  |  |
ZYTIGA / abiraterone acetate |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 16 |  |  | 19 |  |  | (14.0) |  |  |  |  |  |  |
International |  | 229 |  |  | 520 |  |  | (56.0) |  |  |  |  |  |  |
Worldwide |  | 245 |  |  | 539 |  |  | (54.5) |  |  |  |  |  |  |
OTHER ONCOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 92 |  |  | 34 |  |  | * |  |  |  |  |  |
International |  | 70 |  |  | 84 |  |  | (17.2) |  |  |  |  |  |  |
Worldwide |  | 162 |  |  | 118 |  |  | 37.4 |  |  |  |  |  |  |
Pulmonary Hypertension |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 600 |  |  | 572 |  |  | 4.9 |  |  |  |  |  |  |
International |  | 272 |  |  | 279 |  |  | (2.7) |  |  |  |  |  |  |
Worldwide |  | 872 |  |  | 852 |  |  | 2.4 |  |  |  |  |  |  |
OPSUMIT |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 273 |  |  | 273 |  |  | (0.1) |  |  |  |  |  |  |
International |  | 167 |  |  | 170 |  |  | (1.6) |  |  |  |  |  |  |
Worldwide |  | 440 |  |  | 443 |  |  | (0.7) |  |  |  |  |  |  |
UPTRAVI |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 304 |  |  | 269 |  |  | 13.1 |  |  |  |  |  |  |
International |  | 58 |  |  | 56 |  |  | 3.3 |  |  |  |  |  |  |
Worldwide |  | 362 |  |  | 325 |  |  | 11.4 |  |  |  |  |  |  |
OTHER PULMONARY HYPERTENSION |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 23 |  |  | 30 |  |  | (22.4) |  |  |  |  |  |  |
International |  | 47 |  |  | 53 |  |  | (12.6) |  |  |  |  |  |  |
Worldwide |  | 70 |  |  | 83 |  |  | (16.1) |  |  |  |  |  |  |
Cardiovascular / Metabolism / Other |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 715 |  |  | 672 |  |  | 6.3 |  |  |  |  |  |  |
International |  | 212 |  |  | 238 |  |  | (10.8) |  |  |  |  |  |  |
Worldwide |  | 927 |  |  | 910 |  |  | 1.8 |  |  |  |  |  |  |
XARELTO |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 578 |  |  | 508 |  |  | 13.7 |  |  |  |  |  |  |
International |  | — |  |  | — |  |  | — |  |  |  |  |  |  |
Worldwide |  | 578 |  |  | 508 |  |  | 13.7 |  |  |  |  |  |  |
OTHER(2) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 137 |  |  | 164 |  |  | (16.7) |  |  |  |  |  |  |
International |  | 212 |  |  | 238 |  |  | (10.8) |  |  |  |  |  |  |
Worldwide |  | 349 |  |  | 402 |  |  | (13.2) |  |  |  |  |  |  |
TOTAL PHARMACEUTICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 7,023 |  |  | 6,632 |  |  | 5.9 |  |  |  |  |  |  |
International |  | 6,390 |  |  | 6,237 |  |  | 2.4 |  |  |  |  |  |  |
Worldwide |  | 13,413 |  |  | 12,869 |  |  | 4.2 |  |  |  |  |  |  |
MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
Interventional Solutions |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 863 |  |  | 494 |  |  | 74.5 |  |  |  |  |  |  |
International |  | 640 |  |  | 597 |  |  | 7.1 |  |  |  |  |  |  |
Worldwide |  | 1,503 |  |  | 1,092 |  |  | 37.6 |  |  |  |  |  |  |
ELECTROPHYSIOLOGY |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 571 |  |  | 470 |  |  | 21.4 |  |  |  |  |  |  |
International |  | 522 |  |  | 532 |  |  | (1.8) |  |  |  |  |  |  |
Worldwide |  | 1,092 |  |  | 1,002 |  |  | 9.1 |  |  |  |  |  |  |
ABIOMED(3) |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 264 |  |  | — |  |  | * |  |  |  |  |  |
International |  | 60 |  |  | — |  |  | * |  |  |  |  |  |
Worldwide |  | 324 |  |  | — |  |  | * |  |  |  |  |  |
OTHER INTERVENTIONAL SOLUTIONS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 28 |  |  | 24 |  |  | 17.4 |  |  |  |  |  |  |
International |  | 58 |  |  | 65 |  |  | (11.7) |  |  |  |  |  |  |
Worldwide |  | 87 |  |  | 90 |  |  | (3.9) |  |  |  |  |  |  |
Orthopaedics |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 1,363 |  |  | 1,289 |  |  | 5.8 |  |  |  |  |  |  |
International |  | 881 |  |  | 899 |  |  | (2.0) |  |  |  |  |  |  |
Worldwide |  | 2,245 |  |  | 2,188 |  |  | 2.6 |  |  |  |  |  |  |
HIPS |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 241 |  |  | 225 |  |  | 7.3 |  |  |  |  |  |  |
International |  | 149 |  |  | 164 |  |  | (9.0) |  |  |  |  |  |  |
Worldwide |  | 390 |  |  | 389 |  |  | 0.4 |  |  |  |  |  |  |
KNEES |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 226 |  |  | 201 |  |  | 12.4 |  |  |  |  |  |  |
International |  | 142 |  |  | 138 |  |  | 3.4 |  |  |  |  |  |  |
Worldwide |  | 368 |  |  | 339 |  |  | 8.7 |  |  |  |  |  |  |
TRAUMA |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 491 |  |  | 475 |  |  | 3.2 |  |  |  |  |  |  |
International |  | 267 |  |  | 273 |  |  | (2.4) |  |  |  |  |  |  |
Worldwide |  | 757 |  |  | 748 |  |  | 1.2 |  |  |  |  |  |  |
SPINE, SPORTS & OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 406 |  |  | 387 |  |  | 4.7 |  |  |  |  |  |  |
International |  | 323 |  |  | 324 |  |  | (0.3) |  |  |  |  |  |  |
Worldwide |  | 729 |  |  | 712 |  |  | 2.4 |  |  |  |  |  |  |
Surgery |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 975 |  |  | 921 |  |  | 5.9 |  |  |  |  |  |  |
International |  | 1,459 |  |  | 1,513 |  |  | (3.6) |  |  |  |  |  |  |
Worldwide |  | 2,434 |  |  | 2,434 |  |  | 0.0 |  |  |  |  |  |  |
ADVANCED |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 444 |  |  | 417 |  |  | 6.5 |  |  |  |  |  |  |
International |  | 673 |  |  | 729 |  |  | (7.6) |  |  |  |  |  |  |
Worldwide |  | 1,118 |  |  | 1,146 |  |  | (2.5) |  |  |  |  |  |  |
GENERAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 531 |  |  | 504 |  |  | 5.4 |  |  |  |  |  |  |
International |  | 785 |  |  | 784 |  |  | 0.2 |  |  |  |  |  |  |
Worldwide |  | 1,316 |  |  | 1,288 |  |  | 2.2 |  |  |  |  |  |  |
Vision |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 558 |  |  | 521 |  |  | 7.1 |  |  |  |  |  |  |
International |  | 743 |  |  | 736 |  |  | 0.8 |  |  |  |  |  |  |
Worldwide |  | 1,300 |  |  | 1,257 |  |  | 3.4 |  |  |  |  |  |  |
CONTACT LENSES / OTHER |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 444 |  |  | 400 |  |  | 11.1 |  |  |  |  |  |  |
International |  | 509 |  |  | 511 |  |  | (0.3) |  |  |  |  |  |  |
Worldwide |  | 953 |  |  | 910 |  |  | 4.7 |  |  |  |  |  |  |
SURGICAL |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 114 |  |  | 121 |  |  | (6.0) |  |  |  |  |  |  |
International |  | 233 |  |  | 226 |  |  | 3.3 |  |  |  |  |  |  |
Worldwide |  | 347 |  |  | 347 |  |  | 0.1 |  |  |  |  |  |  |
TOTAL MEDTECH |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 3,759 |  |  | 3,225 |  |  | 16.6 |  |  |  |  |  |  |
International |  | 3,722 |  |  | 3,746 |  |  | (0.6) |  |  |  |  |  |  |
Worldwide |  | 7,481 |  |  | 6,971 |  |  | 7.3 |  |  |  |  |  |  |
WORLDWIDE |  |  |  |  |  |  |  |  |  |  |  |
U.S. |  | 12,517 |  |  | 11,414 |  |  | 9.7 |  |  |  |  |  |  |
International |  | 12,229 |  |  | 12,012 |  |  | 1.8 |  |  |  |  |  |  |
Worldwide |  | $ | 24,746 |  |  | 23,426 |  |  | 5.6 | % |  |  |  |  |  |
*Percentage greater than 100% or not meaningful (1) Inclusive of RISPERDAL CONSTA which was previously disclosed separately (2) Inclusive of INVOKANA which was previously disclosed separately
Operating Profit by Segment of Business | EARNINGS/(LOSS) BEFORE PROVISION FOR TAXES BY SEGMENT
|  | Fiscal First Quarter Ended |  |  |
(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | Percent Change |  |  |  |  |  |  |  |  |  |  |
Consumer Health(1) |  | $ | 776 |  |  | 686 |  |  | 13.1 | % |  |  |  |  |  |  |  |  |  |  |
Pharmaceutical(2) |  | 4,444 |  |  | 3,924 |  |  | 13.3 |  |  |  |  |  |  |  |  |  |  |  |
MedTech(3) |  | 1,445 |  |  | 1,477 |  |  | (2.2) |  |  |  |  |  |  |  |  |  |  |
Segment earnings before provision for taxes |  | 6,665 |  |  | 6,087 |  |  | 9.5 |  |  |  |  |  |  |  |  |  |  |  |
Less: Expense not allocated to segments (4) |  | 7,102 |  |  | 123 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Less: Consumer Health separation costs |  | 300 |  |  | 102 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Worldwide income/(loss) before tax |  | $ | (737) |  |  | 5,862 |  |  | * |  |  |  |  |  |  |  |  |  |  |
*Percentage greater than 100% or not meaningful (1) Consumer Health includes: •Intangible amortization expense of $0.1 billion in both the fiscal first quarter of 2023 and 2022. (2) Pharmaceutical includes: •Intangible amortization expense of $0.7 billion and $0.8 billion in the fiscal first quarter of 2023 and 2022, respectively. •COVID-19 Vaccine related exit costs of $0.4 billion in the fiscal first quarter of 2023. •A restructuring related charge of $0.1 billion in the fiscal first quarter of 2023. •In the fiscal first quarter of 2022, the Company recorded an intangible asset impairment charge of approximately $0.6 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). •Unfavorable changes in the fair value of securities in the fiscal first quarter of 2022 of $0.4 billion. (3) MedTech includes: •Intangible amortization expense of $0.4 billion and $0.3 billion in the fiscal first quarter of 2023 and 2022, respectively. •A restructuring related charge of $0.1 billion in the fiscal first quarter of 2022. (4)Amounts not allocated to segments include interest income/expense and general corporate income/expense. The fiscal first quarter of 2023 includes the incremental $6.9 billion charge related to the talc settlement proposal. See Note 11, Legal Proceedings, for additional details.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas | SALES BY GEOGRAPHIC AREA
|  | Fiscal First Quarter Ended |  |
(Dollars in Millions) |  | April 2, 2023 |  | April 3, 2022 |  | Percent Change |  |  |  |  |  |
United States |  | $ | 12,517 |  |  | 11,414 |  |  | 9.7 | % |  |  |  |  |  |
Europe |  | 6,332 |  |  | 6,024 |  |  | 5.1 |  |  |  |  |  |  |
Western Hemisphere, excluding U.S. |  | 1,587 |  |  | 1,482 |  |  | 7.1 |  |  |  |  |  |  |
Asia-Pacific, Africa |  | 4,310 |  |  | 4,506 |  |  | (4.3) |  |  |  |  |  |  |
Total |  | $ | 24,746 |  |  | 23,426 |  |  | 5.6 | % |  |  |  |  |  |

X
- Definition Sales by segment of business. + References No definition available. + Details
Name: | jnj_SalesBySegmentOfBusinessTableTextBlock
Namespace Prefix: | jnj_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -URI https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration